FORM 4

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
Occident 10. Form 4 of Form 5		

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* COVINO GREGORY F						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]										ionship of Reporting all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify		
	t) (First) (Middle) OGEN INC. BINNEY STREET				3. Date of Earliest Transaction (Month/Day/Year) 05/01/2015									below	below) VP, Chief Accounti			·		
(Street) CAMBR (City)			02142 (Zip)		_ 4. I									Line)	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	ative	Sec	uriti	es Ac	quired	Dis	posed	of, or E	enef	iciall	y Owne	d				
Da			2. Transa Date (Month/I	Day/Year) E:		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Di			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			Benefic	es ially Following	Forn (D) c	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) (D)	or P	ice	Transac (Instr. 3	ction(s)			(11311.4)	
Common Stock 05/				05/01	/2015	2015			М		347	A	. \$	386.2	2 1,87	3.968(1)		D		
Common	Stock			05/01	/2015				F		113	Г	\$	386.2	6.22 1,760.968 D					
		Т	able II -								osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	n Date,		ransaction ode (Instr.		1 of		ercisa n Date ny/Yea		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisab		expiration pate	Title	or	ount nber res						
Restricted	\$0	05/01/2015			M			347	(2)		5/01/2016	Commo	ı 3.	47	\$ <mark>0</mark>	348		D		

Explanation of Responses:

Stock Unit

- 1. Includes 73.097 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2015.
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

/s/ Matthew S. Gilman,

Attorney-in-fact for Gregory 05/05/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.